Monitor the outcome of the shareholder vote, particularly the director elections, as the recent board changes (Mihas' resignation and Krause's appointment) indicate potential shifts in governance. The vote on executive compensation is also a key indicator of shareholder sentiment.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 9 $15.28entry
- T+1 · 7mo ago +0.52%α +0.59% · $15.36
- T+5 · 7mo ago +3.60%α +0.41% · $15.83
- T+20 · 6mo ago +3.40%α −4.16% · $15.80
- T+60 · 4mo ago +16.88%α +6.10% · $17.86
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Sotera Health Co filed a definitive proxy statement for its 2026 Annual Meeting, proposing the election of four Class III directors, approval of executive compensation, and ratification of its independent auditor. This filing follows a recent 8-K report detailing the resignation of director Constantine Mihas and the appointment of Kenneth Krause, suggesting board changes are materializing near the shareholder vote.
Key Financial Metrics
Key Facts
- Filing is a definitive proxy statement (DEFA14A) for the 2026 Annual Meeting of Stockholders.
- Proposals include electing four Class III directors (Sean L. Cunningham, Richard G. Kyle, Vincent K. Petrella, Christopher A. Simon), approving executive compensation, and ratifying Ernst & Young as auditor.
- Recent 8-K filing (Items 5.02) reported the resignation of director Constantine Mihas and the appointment of Kenneth Krause.
- The proxy filing context indicates board/executive changes are occurring near the proxy materials, suggesting the vote may be materializing from a prior situation.
Financial Impact
No direct financial impact disclosed in the proxy statement.
Risk Factors
- Potential for shareholder dissent on executive compensation (say-on-pay vote).
- Board composition changes could signal strategic shifts.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001104659-26-040945 |
| Document: 0001104659-26-040945-index-headers.html | 0001104659-26-040945 |
| Document: 0001104659-26-040945-index.html | 0001104659-26-040945 |
| Document: 0001104659-26-040945.txt | 0001104659-26-040945 |
Track record
18 reports on SHC
6 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +16.44% at T+60 after the May 5, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 3, 202613d ago 8-K Neutral 5/10 No price data
- Nov 3, 202613d ago Press Release Bullish 5/10 Entry $16.03 to $16.39 Now $16.25 +1.37% ▲ +2.25% +0.59% vs SPY
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $18.15 to $17.74 Now $16.25 −10.47% ▼ −2.26% −1.78% vs SPY
- Oct 21, 202626d ago Institutional Cluster Neutral 3/10 Entry $18.13 to $18.10 Now $16.25 −10.37% ▼ −0.17% +0.36% vs SPY
- Oct 9, 20265w ago SC 13G/A Bearish 5/10 Entry $18.15 to $18.21 Now $16.25 +10.47% ▼ −0.33% −0.34% vs SPY
- Aug 14, 202613w ago 8-K Neutral 2/10 Entry $18.89 to $18.80 Now $16.25 −13.98% ▼ −0.48% −0.00% vs SPY
- Aug 9, 202614w ago Institutional Cluster Bullish 4/10 Entry $18.97 to $19.11 Now $16.25 −14.34% ▲ +0.74% +1.06% vs SPY
- Aug 7, 202614w ago 144 Neutral 3/10 Entry $18.86 to $18.97 Now $16.25 −13.84% ▲ +0.58% +0.61% vs SPY
- Aug 6, 202614w ago 8-K Bullish 7/10 Entry $18.91 to $18.86 Now $16.25 −14.07% ▼ −0.26% −0.88% vs SPY
- May 27, 202624w ago 3 Neutral 2/10 Entry $15.75 to $15.64 Now $16.25 +3.17% ▼ −0.70% −0.94% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers